T. Rowe Price Investment Management, Inc. Prothena Corp Public LTD CO Transaction History

T. Rowe Price Investment Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $1.07 Million - $1.6 Million	-22,691 Reduced 2.59%	853,479 $41.2 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $1.86 Million - $3.03 Million	-38,513 Reduced 4.21%	876,170 $59.8 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $623,573 - $773,592	-13,276 Reduced 1.43%	914,683 $44.3 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $4.16 Million - $5.2 Million	79,997 Added 9.43%	927,959 $55.9 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $21.3 Million - $51.4 Million	847,962 New	847,962 $51.4 Million

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.